Novartis Ag

Michael D Connolly

Ronald N Zuckermann

David Jonathan Glass

Simone Bonazzi

Andrew William Patterson

Manuel Mihalic

Silvio Roggo

Tea Shavlakadze

David Peretz

Man Gao

Gulliver Timoteo

Robert M Shimizu

The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.

Rapamycin derivatives

The invention relates to peptoid reagents that interact preferentially with a pathogenic form of a conformational disease protein as compared to a nonpathogenic form of the conformational disease protein where the peptoid reagent comprises an amino-terminal region, a carboxy-terminal region, and at least one peptoid region between the amino-terminal region and the carboxy-terminal region where the peptoid region comprises 3 to about 30 N-substituted glycines, and optionally one or more amino acids. The invention also relates to methods of using the peptoids in detecting and isolating prions, and in the treatment and prevention of prion-related diseases.

Prion-specific peptoid reagents

Growing community of inventors

Dublin, CA, United States of America

Michael D Connolly